Our new study reveals trends, R&D progress, and predicted revenues
Our new report discusses issues and events affecting the Parkinson’s disease therapeutics market. Our new report provides qualitative analyses to answer these key questions:
• How is the Parkinson’s disease therapeutics market evolving?
• What is driving and restraining the Parkinson’s disease therapeutics market?
• How will political and regulatory factors influence the regional markets and submarkets?
• Who are the leading Parkinson’s disease therapeutics companies, and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
Forecasts from 2018-2028 and other analyses show you commercial prospects
Our new report provides quantitative analyses to answer these key questions:
• What are the market shares of the Parkinson’s therapeutics disease market in 2017?
• How will each of the drugs in the Parkinson’s therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2028?
• What Parkinson’s disease drugs are in the development pipeline?
• How will each of Parkinson’s disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2028?
• How will the market shares of the national markets change by 2028 and which geographical region will lead the market in 2028?
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments.
Many opportunities exist for the treatment of Parkinson’s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead.
Discover sales predictions for the world market and submarkets
Discover in our report overall world revenue to 2028 for Parkinson’s disease medicines. Also explore individual revenue predictions to 2028 for six therapeutic submarkets at world level:
• Levodopa/ Carbidopa
• Dopamine Receptor Agonists
• MAO-inhibitors
• COMT-inhibitors
• Anticholinergics
• Other Therapeutic Options
Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
This report also breaks down the revenue forecast for the Global Parkinson’s Disease drugs market by Distribution Channel:
• Hospital Pharmacies
• Retailer Pharmacies
• Online Pharmacies
Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.
This report also breaks down the revenue forecast for the Global Parkinson’s Disease drugs market by End-User:
• Hospitals
• Clinics
Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.
What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2017.
Our work also shows individual revenue forecasts to 2028 for 20 national markets:
• North America – US, Canada, Mexico
• South America – Brazil, Argentina, Paraguay, Bolivia
• Europe – Germany, France, UK, Italy, Spain and Russia
• Asia Pacific – China, Japan, India, Australia, Thailand
• ROW – Middle East, Africa
Leading companies and potential for market growth
In 2017 the overall Global Parkinson’s Disease drug market generated $4.10bn. Visiongain predicts its revenues in 2022 to reach $5.70bn. Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:
• Astrazeneca
• Merck &Co.
• Novartis AG
• GlaxoSmith Kline
• Roche
• Pfizer
• Abbvie
• Biogen Inc.
• Acorda Therapeutics Inc
What affects producers of those medicines?
Our report discusses issues and events affecting that industry and market from 2017, including these:
• Research and development (R&D) – drugs, diagnostic tests, and related technologies
• Disease prevalence – expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines – changes and opportunities.
• Drugs and related technologies to transform the market
• Biomarkers
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.
Our 152-page report provides 82 Tables and 85 Figures. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.
Benefit your work now through our updated study, gaining original industry and market analysis:
• Revenues for Parkinson’s disease treatments to 2028 – assess that overall world drugs market’s potential and get forecasted revenues for the six leading sub-classes: Levodopa/Carbidopa, Dopamine receptor agonists, COMT- and MAO-inhibitors, Anticholinergics, and other therapeutic options.
• National market forecasting to 2028 for 20 countries in the Americas, Europe, Asia, Middle East and Africa – explore the best regions for treatment demand, sales and growth
• R&D activities – see progress, trends and prospects in research and development, finding technological, clinical and commercial possibilities
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths there, helping you compete and gain advantages.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Parkinson’s Disease Drug Industry and Market Overview
1.2 Market Definition
1.3 Research Methodology
1.4 Primary Research
1.5 Secondary Research
1.6 Market Evaluation & Forecasting Methodology
1.7 Global Parkinson’s Disease Drug industry and Market Segmentation
1.8 Overview of Findings
1.9 Why You Should Read This Report
1.10 How this report delivers?
1.11 Key Questions Answered by This Analytical Report
1.12 Frequently Asked Questions (FAQ)
1.13 Who is This Report For?
1.14 Associated Visiongain Reports
1.15 About Visiongain
2. Introduction to Global Parkinson’s Disease Drug Industry and Market
3. Global Parkinson’s Disease Drug Industry and Market Forecast to 2028
4. Global Parkinson’s Disease Market, by Drug Type: Market Forecast to 2028
4.1 Overview
4.2 Levodopa/Carbidopa
4.3 Dopamine Receptor Agonists
4.4 MAO-Inhibitors
4.5 COMT-inhibitors
4.6 Anticholinergics
4.7 Other Drugs
5. Global Parkinson’s Disease Drug Industry and Market by Distribution Channel: Market Forecast to 2028
5.1 Overview
5.2 Hospital Pharmacies
5.3 Retailer Pharmacies
5.4 Online Pharmacies
6. Global Parkinson’s Disease Drug Industry and Market by End User: Market Forecast to 2028
6.1 Overview
6.2 Hospitals
6.3 Clinics
7. Leading National Parkinson’s Disease Drug Markets, 2018-2028
8. North American Parkinson’s Disease Drug Industry and Forecast 2018-2028
8.1 US Parkinson’s Disease Drug Industry and Forecast 2018-2028
8.2 Canada Parkinson’s Disease Drug Industry and Forecast 2018-2028
8.3 Mexico Parkinson’s Disease Drug Industry and Forecast 2018-2028
9. South American Parkinson’s Disease Drug Industry and Forecast 2018-2028
9.1 Brazil Parkinson’s Disease Drug Industry and Forecast 2018-2028
9.2 Argentina Parkinson’s Disease Drug Industry and Forecast 2018-2028
9.3 Paraguay Parkinson’s Disease Drug Industry and Forecast 2018-2028
9.4 Bolivia Parkinson’s Disease Drug Industry and Forecast 2018-2028
9.5 Rest of South America Parkinson’s Disease Drug Industry and Forecast 2018-2028
10. European Parkinson’s Disease Drug Industry and Forecast 2018-2028
10.1 France Parkinson’s Disease Drug Industry and Forecast 2018-2028
10.2 Germany Parkinson’s Disease Drug Industry and Forecast 2018-2028
10.3 UK Parkinson’s Disease Drug Industry and Forecast 2018-2028
10.4 Spain Parkinson’s Disease Drug Industry and Forecast 2018-2.028
10.5 Italy Parkinson’s Disease Drug Industry and Forecast 2018-2028
10.6 Russia Parkinson’s Disease Drug Industry and Forecast 2018-2028
10.7 Rest of Europe Parkinson’s Disease Drug Industry and Forecast 2018-2028
11. Asia-Pacific Parkinson’s Disease Drug Industry and Forecast 2018-2028
11.1 China Parkinson’s Disease Drug Industry and Forecast 2018-2028
11.2 Japan Parkinson’s Disease Drug Industry and Forecast 2018-2028
11.3 India Parkinson’s Disease Drug industry and Forecast 2018-2028
11.4 Australia Parkinson’s Disease Drug Industry and Forecast 2018-2028
11.5 Thailand Parkinson’s Disease Drug Industry and Forecast 2018-2028
11.6 Rest of Asia-Pacific Parkinson’s Disease Drug Industry and Forecast 2018-2028
12. Rest of World Parkinson’s Disease Drug Industry and Forecast 2018-2028
12.1 Middle East Parkinson’s Disease Drug Industry and Forecast 2018-2028
12.2 Africa Parkinson’s Disease Drug Industry and Forecast 2018-2028
12.3 Other Countries Parkinson’s Disease Drug Industry and Forecast 2018-2028
13. Parkinson’s Disease Drug industry and Forecast, Qualitative Analysis, 2018-2028
13.1 Porter’s Five Forces Analysis of the Global Parkinson’s disease drug industry and Forecast 2018-2028
13.1.1 Bargaining Power of Buyers (Low)
13.1.2 Bargaining Power of Suppliers (Medium)
13.1.3 Threat of New Entrants (Low)
13.1.4 Threat of Substitute Products (Low)
13.1.5 Intensity of Competitive Rivalry (High)
13.2 Drivers, Restrains & Opportunities
13.2.1 Drivers
13.2.2 Restraints
13.2.3 Opportunities
14. Leading Companies in the Global Parkinson’s Disease Drugs Market
14.1 AstraZeneca Plc
14.1.1 AstraZeneca Plc: Company Overview
14.1.2 AstraZeneca Plc: Product Portfolio
14.1.3 AstraZeneca Plc: Recent Developments
14.2 Merck & Co. Inc.
14.2.1 Merck & Co. Inc.: Company Overview
14.2.2 Merck & Co. Inc.: Product Portfolio
14.3 Novartis AG
14.3.1 Novartis AG: Company Overview
14.3.2 Novartis AG: Product Portfolio
14.4 GlaxoSmithKline PLC
14.4.1 GlaxoSmithKline PLC: Company Overview
14.2 GlaxoSmithKline PLC: Product Portfolio
14.5 F. Hoffmann-La Roche AG
14.5.1 F. Hoffmann-La Roche: Company Overview
14.5.2 F. Hoffmann-La Roche: Product Portfolio
14.5.3 F. Hoffmann-La Roche: Recent Developments
14.6 Pfizer Inc.
14.6.1 Pfizer Inc.: Company Overview
14.6.2 Pfizer Inc.: Product Portfolio
14.6.3 Pfizer: Recent Developments
14.7 Abbvie Inc.
14.7.1 Abbvie Inc.: Company Overview
14.7.2 Abbvie Inc.: Product Portfolio
14.7.3 Abbvie Inc.: Recent Developments
14.8 Biogen Inc.
14.8.1 Biogen Inc.: Company Overview
14.8.2 Biogen Inc.: Product Portfolio
14.8.3 Biogen Inc.: Recent Developments
14.9 Acorda Therapeutics, Inc.
14.9.1 Acorda Therapeutics, Inc.: Company Overview
14.9.2 Acorda Therapeutics, Inc.: Product Portfolio
14.9.3 Acorda Therapeutics, Inc.: Recent Developments
14.10 UCB S.A.
14.10.1 UCB S.A.: Company Overview
14.10.2 UCB S.A.: Product Portfolio
15. Conclusions
15.1.1 Current Leading Segments
15.1.2 Leading Regional Markets
15.1.3 Emerging Markets
15.1.4 The Future of the Market?
Table of Tables
Table 3.1. Global Parkinson’s Disease Drug Industry and Market Forecast ($bn, AGR%, CAGR%) 2018-2028
Table 4.1 Global Parkinson’s Disease Market, by Drug Type, Forecast ($bn, AGR%, CAGR%) 2018-2028
Table 4.2 Global Parkinson’s Disease Market Forecast for Levodopa/Carbidopa Drugs, ($bn, AGR%, CAGR%) 2018-2028
Table 4.3 Global Parkinson’s Disease Market Forecast for Levodopa/Carbidopa Drugs, by Geography, ($bn, AGR%, CAGR%) 2017-2028
Table 4.4 Global Parkinson’s Disease Market Forecast for Dopamine Receptor Agonists Drugs, ($bn, AGR%, CAGR%) 2018-2028
Table 4.5 Global Parkinson’s Disease Market Forecast for Dopamine Receptor Agonists Drugs, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 4.6 Global Parkinson’s Disease Market Forecast for MAO-Inhibitors Drugs, ($bn, AGR%, CAGR%) 2018-2028
Table 4.7 Global Parkinson’s Disease Market Forecast for MAO-Inhibitors Drugs, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 4.8 Global Parkinson’s Disease Market Forecast for COMT-inhibitors Drugs, ($bn, AGR%, CAGR%) 2018-2028
Table 4.9 Global Parkinson’s Disease Market Forecast for COMT-inhibitors Drugs, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 4.10 Global Parkinson’s Disease Market Forecast for Anticholinergics Drugs, ($bn, AGR%, CAGR%) 2018-2028
Table 4.11 Global Parkinson’s Disease Market Forecast for Anticholinergics Drugs, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 4.12 Global Parkinson’s Disease Market Forecast for Others Drugs, ($bn, AGR%, CAGR%) 2018-2028
Table 4.13 Global Parkinson’s Disease Market Forecast for Others Drugs, ($bn, AGR%, CAGR%) 2018-2028
Table 5.1. Global Parkinson’s Disease Market Forecast for Distribution Channel ($bn, AGR%, CAGR%) 2018-2028
Table 5.2 Global Parkinson’s Disease Market Forecast for Hospital Pharmacies, ($bn, AGR%, CAGR%) 2018-2028
Table 5.3 Global Parkinson’s Disease Market Forecast for Hospital Pharmacies, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 5.4 Global Parkinson’s Disease Market Forecast for Retailer Pharmacies ($bn, AGR%, CAGR%) 2018-2028
Table 5.5 Global Parkinson’s Disease Market Forecast for Retailer Pharmacies, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 5.6 Global Parkinson’s Disease Market Forecast for Online Pharmacies ($bn, AGR%, CAGR%) 2018-2028
Table 5.7 Global Parkinson’s Disease Market Forecast for Online Pharmacies, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 6.1 Global Parkinson’s Disease Market Forecast for End User ($bn, AGR%, CAGR%) 2018-2028
Table 6.2 Global Parkinson’s Disease Market Forecast by Hospitals, ($bn, AGR%, CAGR%) 2018-2028
Table 6.3 Global Parkinson’s Disease Market Forecast by Hospitals, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 6.4 Global Parkinson’s Disease Market Forecast by Clinics ($bn, AGR%, CAGR%) 2018-2028
Table 6.5 Global Parkinson’s Disease Market Forecast by Clinics, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 7.1. Global Parkinson’s Disease Market Forecast, by Geography ($bn, AGR%, CAGR%) 2018-2028
Table 8.1 North America Parkinson’s Disease Drug industry and Forecast, by Country ($bn, AGR%, CAGR%) 2018-2028
Table 8.2 US Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 8.3 Canada Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 8.4 Mexico Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 9.1 South America Parkinson’s Disease Drug industry and Forecast, by Country ($bn, AGR%, CAGR%) 2018-2028
Table 9.2 Brazil Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 9.3 Argentina Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 9.4 Paraguay Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 9.5 Bolivia Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 9.6 Rest of South America Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 10.1 European Parkinson’s Disease Drug industry and Forecast, by Country ($bn, AGR%, CAGR%) 2018-2028
Table 10.2 France Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 10.3 Germany Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 10.4 UK Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 10.5 Spain Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 10.6 Italy Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 10.7 Russia Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 10.8 Rest of European Parkinson’s Disease Drug industry and Forecast, ($bn, AGR%, CAGR%) 2018-2028
Table 11.1 Asia-Pacific Parkinson’s Disease Drug industry and Forecast, by Country ($bn, AGR%, CAGR%) 2018-2028
TableFigure 4.8 Global Parkinson’s Disease Market Forecast for Others Drugs, by Geography, ($bn) 2018-2028
Figure 5.1. Global Parkinson’s Disease Market Forecast for Distribution Channel, Market Share (%), 2017
Figure 5.2. Global Parkinson’s Disease Market Forecast for Hospital Pharmacies, by Geography ($bn) 2018-2028
Figure 5.3 Global Parkinson’s Disease Market Forecast for Retailer Pharmacies, by Geography ($bn) 2018-2028
Figure 5.4 Global Parkinson’s Disease Market Forecast for Online Pharmacies, by Geography ($bn) 2018-2028
Figure 6.1 Global Parkinson’s Disease Market Forecast for End User, Market Share (%), 2017
Figure 6.2 Global Parkinson’s Disease Market Forecast by Hospitals, by Geography ($bn) 2018-2028
Figure 6.3 Global Parkinson’s Disease Market Forecast by Clinics, by Geography ($bn) 2018-2028
Figure 7.1. Global Parkinson’s Disease Market Forecast, by Geography, by Geography ($bn) 2018-2028
Figure 7.2. Global Parkinson’s Disease Market Forecast, by Geography, Market Share (%), 2017
Figure 8.1 North America Parkinson’s Disease Drug industry and Forecast, by Country ($bn) 2018-2028
Figure 8.2 North America Parkinson’s Disease Drug industry and Forecast, by Country, Market Share (%), 2017
Figure 8.3 US Parkinson’s Disease Drug industry and Forecast, ($bn) 2018-2028
Figure 8.4 Canada Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 8.5 Mexico Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 9.1 South America Parkinson’s Disease Drug industry and Forecast, by Country ($bn) 2018-2028
Figure 9.2 South America Parkinson’s Disease Drug industry and Forecast, by Country, Market Share (%), 2017
Figure 9.3 Brazil Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 9.4 Argentina Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 9.5 Paraguay Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 9.6 Bolivia Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 9.7 Rest of South America Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 10.1 Europe Parkinson’s Disease Drug industry and Forecast, by Country ($bn) 2018-2028
Figure 10.2 Europe Parkinson’s Disease Drug industry and Forecast, by Country, Market Share (%), 2017
Figure 10.3 France Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 10.4 Germany Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 10.5 UK Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 10.6 Spain Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 10.7 Italy Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 10.8 Russia Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 10.9 Rest of Europe Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 11.1 Asia-Pacific Parkinson’s Disease Drug industry and Forecast, by Country ($bn) 2018-2028
Figure 11.2 Asia-Pacific Parkinson’s Disease Drug Industry and Forecast, Market Share (%), 2017
Figure 11.3 China Parkinson’s Disease Drug Industry and Forecast ($bn) 2018-2028
Figure 11.4 Japan Parkinson’s Disease Drug Industry and Forecast ($bn) 2018-2028
Figure 11.5 India Parkinson’s Disease Drug Industry and Forecast ($bn) 2018-2028
Figure 11.6 Australia Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 11.7 Thailand Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 11.8 Rest of Asia-Pacific Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 12.1 RoW Parkinson’s Disease Drug industry and Forecast, by Country($bn) 2018-2028
Figure 12.2 Rest of World Parkinson’s Disease Drug industry and Forecast, by Country, Market Share (%), 2017
Figure 12.3 Middle East Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 12.4 Africa Parkinson’s Disease Drug Industry and Forecast ($bn) 2018-2028
Figure 12.5 Other Countries Parkinson’s Disease Drug industry and Forecast ($bn) 2018-2028
Figure 13.1 Porter’s Five Forces Analysis of the Parkinson’s Disease Drug Market
Figure 14.1 AstraZeneca Plc, Revenue, ($million), 2012-2016
Figure 14.2 AstraZeneca Plc, Product Segments Share (%), 2016
Figure 14.3 Merck & Co. Inc., Revenue, ($million), 2012-2016
Figure 14.4 Merck & Co. Inc., Product Segments Share (%), 2016
Figure 14.5 Merck & Co. Inc., Geographical Presence Share (%), 2016
Figure 14.6 Novartis AG, Revenue, ($million), 2012-2016
Figure 14.7 Novartis AG, Product Segments Share (%), 2016
Figure 14.8 Novartis AG, Geographical Presence Share (%), 2016
Figure 14.9 GlaxoSmithKline PLC, Revenue, ($million), 2012-2016
Figure 14.10 GlaxoSmithKline PLC, Product Segments Share (%), 2016
Figure 14.11 GlaxoSmithKline PLC, Geographical Presence Share (%), 2016
Figure 14.12 F. Hoffmann-La Roche, Revenue, ($million), 2012-2016
Figure 14.13 F. Hoffmann-La Roche, Product Segments Share (%), 2016
Figure 14.14 F. Hoffmann-La Roche, Geographical Presence Share (%), 2016
Figure 14.15 Pfizer Inc., Revenue, ($million), 2012-2016
Figure 14.16 Pfizer Inc., Product Segments Share (%), 2016
Figure 14.17 Pfizer Inc., Geographical Presence Share (%), 2016
Figure 14.18 Abbvie Inc., Revenue, ($million), 2012-2016
Figure 14.19 Abbvie Inc., Product Segments Share (%), 2016
Figure 14.20 Abbvie Inc., Geographical Presence Share (%), 2016
Figure 14.21 Biogen Inc., Revenue, ($million), 2012-2016
Figure 14.22 Biogen Inc., Product Segments Share (%), 2016
Figure 14.23 Biogen Inc., Geographical Presence Share (%), 2016
Figure 14.24 Acorda Therapeutics, Inc., Revenue, ($million), 2012-2016
Figure 14.25 UCB S.A., Revenue, ($million), 2012-2016
Figure 15.1 World Parkinson’s Disease Drugs Market, by Drug Class, ($bn), 2018-2028
Figure 15.2 World Parkinson’s Disease Drugs Market, by Distribution Channel, ($bn), 2018-2028
Figure 15.3 World Parkinson’s Disease Drugs Market, by End-User, ($bn), 2018-2028
Figure 15.4. World Parkinson’s Disease Drugs Market, by Geography, ($bn), 2018-2028
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
